Results 101 to 110 of about 61,437 (248)

Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. [PDF]

, 2019
The goal of the Sexually Transmitted Infection Clinical Trial Group's Antimicrobial Resistance (AMR) in Neisseria gonorrhoeae (NG) meeting was to assemble experts from academia, government, nonprofit and industry to discuss the current state of research,
Bristow, Claire C, Cristillo, Anthony D, Dillon, Jo-Anne, Dong, Huan, Grad, Yonatan H, Kirkcaldy, Robert D, Klausner, Jeffrey D, Lawrence, Kenneth, Morris, Sheldon R, Nicholas, Robert A, Oldach, David, Rice, Peter A, Shafer, William Maurice, Torrone, Elizabeth, Wi, Teodora E, Zhou, Pei   +15 more
core   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]

, 2007
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross, Pavlakis, Nick, Stordal, Britta   +2 more
core   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Idris Bahce, Medhat M. Said, Jan Buter, Harmen Huls, Paolo Magni, Imke Bartelink   +10 more
wiley   +1 more source

A pH‐responsive charge‐reversal liposome with enhanced biofilm penetration for multimodal synergistic therapy of bacterial infections

BMEMat, EarlyView.
This study develops a pH‐responsive, charge‐reversal liposome for treating bacterial biofilm infections. With enhanced penetration capability, the liposome effectively delivers antibacterial agents into biofilms. By integrating photodynamic and photothermal therapies with antibiotics, it significantly eradicates biofilms and accelerates bacteria ...
Ruyue Li, Bo Liu, Cheng Wang, Zhencheng Sun, Shuyi Lv, Liang Tian, Minghui Xiao, Qinyang Zheng, Linqi Shi, Chunlei Zhu   +9 more
wiley   +1 more source

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. [PDF]

, 2017
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled
Boin, Francesco, Carns, Mary, Chung, Lorinda, Criswell, Lindsey A, Derk, Chris T, Domsic, Robyn T, Gladue, Heather, Goldberg, Avram, Gordon, Jessica K, Gourh, Pravitt, Hsu, Vivien, Jan, Reem, Kastner, Daniel L, Khanna, Dinesh, Mayes, Maureen D, Medsger, Thomas A, Morgan, Nadia D, Ramos, Paula S, Remmers, Elaine F, Saketkoo, Lesley A, Schiopu, Elena, Shah, Ami A, Shanmugam, Victoria K, Silver, Richard M, Steen, Virginia D, Trojanowski, Marcin A, Valenzuela, Antonia, Varga, John, Wigley, Fredrick M   +28 more
core   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, EarlyView.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1 [PDF]

, 2012
The abortive activity of topoisomerases can result in clastogenic and/or lethal DNA damage in which the topoisomerase is covalently linked to the 3'- or 5'-terminus of a DNA strand break. This type of DNA damage is implicated in chromosome translocations
Abhishek Sharma, Barthelmes, Danny Huylebroeck, Davies, Davies, El-Khamisy, El-Khamisy, El-Khamisy, El-Khamisy, Esguerra, Giovanella, Hirano, Hudson, Interthal, Interthal, Junko Murai, Katyal, Keith W. Caldecott, Ledesma, Liesbeth Vermeire, Lieve Umans, Limei Ju, Murai, Nitiss, Pommier, Pommier, Pype, Sherif F. El-Khamisy, Shunichi Takeda, Takashima, Varady, Vilotti, Yang, Yves Pommier, Zeng, Zhihong Zeng, Zhou   +36 more
core   +1 more source

Topoisomerase I Inhibitors.

The oncologist
Topoisomerase I inhibitors are a new class of anticancer agents with a mechanism of action aimed at interrupting DNA replication in cancer cells, the result of which is cell death. Most if not all Topoisomerase I inhibitors are derivatives of the plant extract camptothecin.
, Ewesuedo, , Ratain
openaire   +1 more source